Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report

AbbVie's Humira has been topping pharma's sales charts, but in a few years it'll be passed by Merck's Keytruda and several other meds, a GlobalData forecast shows. Also in the top 10 are Bristol and Pfizer's Eliquis, Celgene's Revlimid, and BMS' Opdivo.